Literature DB >> 20220521

Sickle cell trait, hemoglobin C trait, and invasive pneumococcal disease.

Katherine A Poehling1, Laney S Light, Melissa Rhodes, Beverly M Snively, Natasha B Halasa, Ed Mitchel, William Schaffner, Allen S Craig, Marie R Griffin.   

Abstract

BACKGROUND: The cause of historically higher rates of invasive pneumococcal disease among blacks than whites has remained unknown. We tested the hypothesis that sickle cell trait or hemoglobin C trait is an independent risk factor for invasive pneumococcal disease.
METHOD: Eligible children were born in Tennessee (1996-2003), had a newborn screen, enrolled in TennCare aged <1 year, and resided in a Tennessee county with laboratory-confirmed, pneumococcal surveillance. Race/ethnicity was ascertained from birth certificates. Children were followed through 2005 until loss of enrollment, pneumococcal disease episode, fifth birthday, or death. We calculated incidence rates by race/ethnicity and hemoglobin type before and after pneumococcal conjugate vaccine (PCV7) introduction. Poisson regression analyses compared invasive pneumococcal disease rates among blacks with sickle cell trait or hemoglobin C trait with whites and blacks with normal hemoglobin, controlling for age, gender, time (pre-PCV7, transition year, or post-PCV7) and high-risk conditions (eg, heart disease).
RESULTS: Over 10 years, 415 invasive pneumococcal disease episodes occurred during 451,594 observed child-years. Before PCV7 introduction, disease rates/100,000 child-years were 2941 for blacks with sickle cell disease, 258 for blacks with sickle cell trait or hemoglobin C trait and 188, 172, and 125 for blacks, whites, and Hispanics with normal hemoglobin. Post-PCV7, rates declined for all groups. Blacks with sickle cell trait or hemoglobin C trait had 77% (95% CI = 22-155) and 42% (95% CI = 1-100) higher rates than whites and blacks with normal hemoglobin.
CONCLUSION: Black children with sickle cell trait or hemoglobin C trait have an increased risk of invasive pneumococcal disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20220521      PMCID: PMC3881008          DOI: 10.1097/EDE.0b013e3181d61af8

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  52 in total

1.  Sickle trait and its association with birthweight and urinary tract infections in pregnancy.

Authors:  I C Baill; F R Witter
Journal:  Int J Gynaecol Obstet       Date:  1990-09       Impact factor: 3.561

2.  Haemoglobin C protects against clinical Plasmodium falciparum malaria.

Authors:  D Modiano; G Luoni; B S Sirima; J Simporé; F Verra; A Konaté; E Rastrelli; A Olivieri; C Calissano; G M Paganotti; L D'Urbano; I Sanou; A Sawadogo; G Modiano; M Coluzzi
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

3.  32-DFP and 51-Cr for measurement of red cell life span in abnormal hemoglobin syndromes.

Authors:  P R McCurdy
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

4.  Pregnancy in women with sickle cell trait.

Authors:  S M Tuck; J W Studd; J M White
Journal:  Br J Obstet Gynaecol       Date:  1983-02

5.  Evaluation of cation-exchange HPLC compared with isoelectric focusing for neonatal hemoglobinopathy screening.

Authors:  M Campbell; J S Henthorn; S C Davies
Journal:  Clin Chem       Date:  1999-07       Impact factor: 8.327

6.  Urea resolves gross hematuria in a 15 year old with hemoglobin C trait.

Authors:  A Sakarcan; J Stallworth
Journal:  Pediatr Nephrol       Date:  2001-02       Impact factor: 3.714

7.  Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.

Authors:  Natasha B Halasa; Sadhna M Shankar; Thomas R Talbot; Patrick G Arbogast; Ed F Mitchel; Winfred C Wang; William Schaffner; Allen S Craig; Marie R Griffin
Journal:  Clin Infect Dis       Date:  2007-04-18       Impact factor: 9.079

8.  Active bacterial core surveillance of the emerging infections program network.

Authors:  A Schuchat; T Hilger; E Zell; M M Farley; A Reingold; L Harrison; L Lefkowitz; R Danila; K Stefonek; N Barrett; D Morse; R Pinner
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

9.  Recurrent hematuria in 4 white patients with sickle cell trait.

Authors:  E Oksenhendler; B Bourbigot; F Desbazeille; D Droz; C Choquenet; R Girot; P Jungers
Journal:  J Urol       Date:  1984-12       Impact factor: 7.450

10.  An immune basis for malaria protection by the sickle cell trait.

Authors:  Thomas N Williams; Tabitha W Mwangi; David J Roberts; Neal D Alexander; David J Weatherall; Sammy Wambua; Moses Kortok; Robert W Snow; Kevin Marsh
Journal:  PLoS Med       Date:  2005-05-31       Impact factor: 11.069

View more
  6 in total

1.  Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications.

Authors:  Jonathan C Goldsmith; Vence L Bonham; Clinton H Joiner; Gregory J Kato; Allan S Noonan; Martin H Steinberg
Journal:  Am J Hematol       Date:  2012-02-03       Impact factor: 10.047

2.  Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009.

Authors:  Amanda B Payne; Ruth Link-Gelles; Ijeoma Azonobi; W Craig Hooper; Bernard W Beall; James H Jorgensen; Billie Juni; Matthew Moore
Journal:  Pediatr Infect Dis J       Date:  2013-12       Impact factor: 2.129

3.  Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study.

Authors:  J Anthony G Scott; James A Berkley; Isaiah Mwangi; Lucy Ochola; Sophie Uyoga; Alexander Macharia; Carolyne Ndila; Brett S Lowe; Salim Mwarumba; Evasius Bauni; Kevin Marsh; Thomas N Williams
Journal:  Lancet       Date:  2011-09-06       Impact factor: 79.321

4.  Immunogenicity of pneumococcal vaccination in a patient with sickle hemoglobinopathy: a case report.

Authors:  E Leila Jerome Clay; Tierra Burrell; Thomas Belhorn; Rupa Redding-Lallinger
Journal:  Clin Case Rep       Date:  2015-06-05

5.  Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers.

Authors:  Steven M Szczepanek; Sean Roberts; Kara Rogers; Christina Cotte; Alexander J Adami; Sonali J Bracken; Sharon Salmon; Eric R Secor; Roger S Thrall; Biree Andemariam; Dennis W Metzger
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

Review 6.  The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe.

Authors:  M A Rose; D Christopoulou; T T H Myint; I de Schutter
Journal:  Int J Clin Pract       Date:  2013-07-19       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.